Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 4, 2011, Pages 928-935

  Vernaz, Nathalie ^a   Huttner, Benedikt ^a   Muscionico, Daniel ^b   Salomon, Jean Luc ^b   Bonnabry, Pascal ^a   López Lozano, José Maria ^c   Beyaert, Arielle ^d   Schrenzel, Jacques ^a   Harbarth, Stephan ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Invoice Office   (Switzerland)

^c HOSPITAL VEGA BAJA   (Spain)

^d UNIVERSITY OF MURCIA   (Spain)

Author keywords

Antibiotic resistance; E. coli; Extended spectrum lactamase producing bacteria; Fluoroquinolone resistance; Health policy making; Time series analysis; Transfer function model

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM; CEFAZOLIN; CEFEPIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; ESCHERICHIA COLI; HOSPITAL PATIENT; HOSPITAL PHARMACY; NONHUMAN; OBSERVATIONAL METHOD; OUTPATIENT DEPARTMENT; RETROSPECTIVE STUDY; URBAN AREA;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HOSPITALS; HUMANS; MODELS, STATISTICAL; RETROSPECTIVE STUDIES;

EID: 79952807466     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq525     Document Type: Article

References (45)

1. Filippini M, Masiero G, Moschetti K. Socioeconomic determinants of regional differences in outpatient antibiotic consumption: evidence from Switzerland. Health Policy 2006; 78: 77-92.
2. Goossens H, Ferech M, Vander Stichele R et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365: 579-87.
3. Schweizerisches Zentrum für Antibiotikaresistenzen (anresis.ch). www. search.ifik.unibe.ch (18 November 2010, date last accessed).
4. European Antimicrobial Resistance Surveillance System. http://www. rivm.nl/earss/database (7 July 2009, date last accessed).
5. Gagliotti C, Nobilio L, Moro ML. Emergence of ciprofloxacin resistance in Escherichia coli isolates from outpatient urine samples. Clin Microbiol Infect 2007; 13: 328-31.
6. Jensen US, Skjot-Rasmussen L, Olsen SS et al. Consequences of increased antibacterial consumption and change in pattern of antibacterial use in Danish hospitals. J Antimicrob Chemother 2009; 63: 812-5.
7. van de Sande-Bruinsma N, Grundmann H, Verloo D et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008; 14: 1722-30.
8. Ortega M, Marco F, Soriano A et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009; 63: 568-74.
9. Friedmann R, Raveh D, Zartzer E et al. Prospective evaluation of colonization with extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae among patients at hospital admission and of subsequent colonization with ESBL-producing Enterobacteriaceae among patients during hospitalization. Infect Control Hosp Epidemiol 2009; 30: 534-42.
10. Cooper BS, Medley GF, Stone SP et al. Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes. Proc Natl Acad Sci USA 2004; 101: 10223-8.
11. Vernaz N, Sax H, Pittet D et al. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. J Antimicrob Chemother 2008; 62: 601-7.
12. Harbarth S, Levine GL, Jarvis WR et al. Computerized pharmacy databases as source of data on antimicrobial prescriptions in children's hospitals. Am J Health Syst Pharm 2001; 58: 2069-71.
13. ATC Index with DDDs, 2007. WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway.
14. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests-Tenth Edition: Approved Standard M02-A10. CLSI, Wayne, PA, USA, 2009.
15. Fankhauser C, Zingg W, Francois P et al. Surveillance of extended-spectrum-β-lactamase-producing Enterobacteriaceae in a Swiss tertiary care hospital. Swiss Med Wkly 2009; 139: 747-51.
16. Harbarth S, Martin Y, Rohner P et al. Effect of delayed infection control measures on a hospital outbreak of methicillin-resistant Staphylococcus aureus. J Hosp Infect 2000; 46: 43-9.
17. Lopez-Lozano JM, Monnet DL, Yague A et al. Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: a time series analysis. Int J Antimicrob Agents 2000; 14: 21-31.
18. Stone SP, Cooper BS, Kibbler CC et al. The ORION statement: guidelines for transparent reporting of outbreak reports and intervention studies of nosocomial infection. J Antimicrob Chemother 2007; 59: 833-40.
19. Helfenstein U. Box-Jenkins modelling in medical research. Stat Methods Med Res 1996; 5: 3-22.
20. Kaier K, Frank U, Hagist C et al. The impact of antimicrobial drug consumption and alcohol-based hand rub use on the emergence and spread of extended-spectrum (-lactamase-producing strains: a time-series analysis. J Antimicrob Chemother 2009; 63: 609-14.
21. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008; 13: pii=19044.
22. Goettsch W, van Pelt W, Nagelkerke N et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands. J Antimicrob Chemother 2000; 46: 223-8.
23. Enne VI, Livermore DM, Stephens P et al. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 2001; 357: 1325-8.
24. Bean DC, Livermore DM, Hall LM. Plasmids imparting sulfonamide resistance in Escherichia coli: implications for persistence. Antimicrob Agents Chemother 2009; 53: 1088-93.
25. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010; 8: 260-71.
26. Colgan R, Johnson JR, Kuskowski M et al. Risk factors for trimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated cystitis. Antimicrob Agents Chemother 2008; 52: 846-51.
27. Talan DA, Krishnadasan A, Abrahamian FM et al. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 2008; 47: 1150-8.
28. Coenen S, Ferech M, Haaijer-Ruskamp FM et al. European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe. Qual Saf Health Care 2007; 16: 440-5.
29. Kuster SP, Ruef C, Bollinger AK et al. Correlation between case mix index and antibiotic use in hospitals. J Antimicrob Chemother 2008; 62: 837-42.
30. Vander Stichele RH, Elseviers MM, Ferech M et al. Hospital consumption of antibiotics in 15 European countries: results of the ESAC Retrospective Data Collection (1997-2002). J Antimicrob Chemother 2006; 58: 159-67.
31. Pakyz A, Powell JP, Harpe SE et al. Diversity of antimicrobial use and resistance in 42 hospitals in the United States. Pharmacotherapy 2008; 28: 906-12.
32. MacDougall C, Powell JP, Johnson CK et al. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005; 41: 435-40.
33. Lautenbach E, Strom BL, Nachamkin I et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004; 38: 655-62.
34. Gallini A, Degris E, Desplas M et al. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital. J Antimicrob Chemother 2010; 65: 2650-7.
35. Harbarth S, Samore MH. Interventions to control MRSA: high time for time-series analysis? J Antimicrob Chemother 2008; 62: 431-3.
36. Ben-Ami R, Rodriguez-Bano J, Arslan H et al. A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49: 682-90.
37. Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M β-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 2010; 35: 316-21.
38. Harbarth S, Harris AD, Carmeli Y et al. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in Gram-negative bacilli. Clin Infect Dis 2001; 33: 1462-8.
39. Polk RE, Fox C, Mahoney A et al. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis 2007; 44: 664-70.
40. Bauraind I, Lopez-Lozano JM, Beyaert A et al. Association between antibiotic sales and public campaigns for their appropriate use. JAMA 2004; 292: 2468-70.
41. Sabuncu E, David J, Bernede-Bauduin C et al. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007. PLoS Med 2009; 6: e1000084.
42. Lautenbach E, Metlay JP, Weiner MG et al. Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance. Infect Control Hosp Epidemiol 2009; 30: 18-24.
43. Lautenbach E, Metlay JP, Mao X et al. The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients. Clin Infect Dis 2010; 51: 280-5.
44. Davey P, Brown E, Fenelon L et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis 2006; 12: 211-6.
45. Gottesman BS, Carmeli Y, Shitrit P et al. Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis 2009; 49: 869-75.